Laekna, Inc. (HKG:2105)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
14.41
-0.65 (-4.32%)
At close: Apr 29, 2026
1.05%
Market Cap 6.06B
Revenue (ttm) 118.76M
Net Income (ttm) -255.19M
Shares Out 420.55M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,767,500
Average Volume 3,309,183
Open 15.13
Previous Close 15.06
Day's Range 14.23 - 15.13
52-Week Range 10.30 - 23.50
Beta -1.00
RSI 38.89
Earnings Date May 13, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 83
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2105
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.